Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 1;8(2):36-45.
doi: 10.36469/001c.26129. eCollection 2021.

A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy

Christina Soeun Kwon  1 , Patrick Daniele  1 , Anna Forsythe  1 , Christopher Ngai  2
Affiliations

A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy

Christina Soeun Kwon et al. J Health Econ Outcomes Res. .

Abstract

Introduction: This systematic literature review analyzed published evidence on IgA nephropathy (IgAN), focusing on US epidemiology, health-related quality of life (HRQoL), and economic burden of illness. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Embase®, MEDLINE®, Cochrane, and Econlit (January 2010 to June 2020) were searched, along with relevant congresses (2017-2020). Results: Of 123 epidemiologic studies selected for data extraction, 24 reported IgAN diagnosis rates ranging from 6.3% to 29.7% among adult and pediatric patients undergoing renal biopsy, with all reported US rates <15%. No US studies reported IgAN prevalence. A meta-analysis of US studies calculated an annual incidence of 1.29/100 000 people, translating to an annual US incidence of 4236 adults and children. Relative to Europe, the United States had more patients diagnosed with IgAN in later chronic kidney disease stages. US rates of transition to end-stage renal disease (ESRD) ranged from 12.5% to 23% during 3-3.9 years of observation, rising to 53% during 19 years of observation. Across 8 studies reporting HRQoL, pain and fatigue were the most reported symptoms, and patients consistently ranked kidney function and mortality as the most important treatment outcomes. Patients with glomerulopathy reported worse mental health than healthy controls or hemodialysis patients; proteinuria was significantly associated with poorer HRQoL and depression. Conclusion: While economic evidence in IgAN remains sparse, management of ESRD is a major cost driver. IgAN is a rare disease where disease progression causes increasing patient burden, underscoring the need for therapies that prevent kidney function decline and HRQoL deterioration while reducing mortality.

Keywords: chronic kidney disease; end-stage renal disease; epidemiology; glomerular nephropathy; immunoglobulin a nephropathy; renal biopsy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study Selection for the Epidemiology SLR
Figure 2.
Figure 2.. Study Design Distribution Among Included Epidemiologic Studies
Figure 3.
Figure 3.. Study Selection for the BOI SLR
See this image and copyright information in PMC

References

    1. Immunoglobulin A nephropathy: A pathophysiology view. Fabiano Rafaela Cabral Gonçalves, Pinheiro Sérgio Veloso Brant, Simões e Silva Ana Cristina. Jun 28;2016 Inflammation Research. 65(10):757–770. doi: 10.1007/s00011-016-0962-x. doi: 10.1007/s00011-016-0962-x. - DOI - DOI - PubMed
    1. IgA nephropathy. Lai Kar Neng, Tang Sydney C. W., Schena Francesco Paolo, Novak Jan, Tomino Yasuhiko, Fogo Agnes B., Glassock Richard J. Feb 11;2016 Nature Reviews Disease Primers. 2(1):16001. doi: 10.1038/nrdp.2016.1. doi: 10.1038/nrdp.2016.1. - DOI - DOI - PubMed
    1. IgA nephropathy. Rodrigues Jennifer C., Haas Mark, Reich Heather N. Feb 3;2017 Clin J Am Soc Nephrol. 12(4):677–686. doi: 10.2215/cjn.07420716. doi: 10.2215/cjn.07420716. - DOI - DOI - PMC - PubMed
    1. Natural history of primary IgA nephropathy. Berthoux François C., Mohey Hesham, Afiani Aïda. Jan;2008 Seminars in Nephrology. 28(1):4–9. doi: 10.1016/j.semnephrol.2007.10.001. doi: 10.1016/j.semnephrol.2007.10.001. - DOI - DOI - PubMed
    1. The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. McGrogan A., Franssen C. F. M., de Vries C. S. 2011Nephrology Dialysis Transplantation. 26(2):414–430. doi: 10.1093/ndt/gfq665. doi: 10.1093/ndt/gfq665. - DOI - DOI - PubMed

LinkOut - more resources